Chordoma Disease Market Analysis

Global Chordoma Disease Market Overview

Chordoma Disease Market Size was valued at USD 3.74 Billion in 2023. The Chordoma Disease market industry is projected to grow from USD 4.34 Billion in 2024 to USD 6.38 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.91% during the forecast period (2024 - 2032). The ageing population, expanding government measures to raise awareness of bone cancer, and the rising incidence of bone cancer are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

In January 2024, Guardant Health disclosed interim findings from the COSMOS study during the ASCO GI Symposium focusing on Guardant Reveal, whose predictive capacity for disease recurrence in early-stage colon cancer has been assessed. Moreover, Guardant Health obtained coverage from some major US commercial health insurers for its Guardant360 test in May 2023, which facilitated the access to broad genomic profiling services tailored for persons with malignant growths​​.

In April 2023, Foundation Medicine expanded its collaboration with Natera so as to incorporate their liquid biopsy technology with FoundationOne CDx, thereby enhancing comprehensive genomic profiling for cancer patients. This agreement is intended to advance diagnosis and treatment of different kinds of malignancies that may as well be useful in terms of chordoma treatment landscape​.

In March 2023, Bayer's subsidiary Loxo Oncology commenced phase II clinical trials for LOXO-292 (selpercatinib), a drug designed against RET-altered tumors. This research complements Bayer’s attempt at understanding gene and molecular abnormalities associated with various types of cancers like chordoma, thereby leading to targeted therapies development​.

In August 2022, Pfizer finalized its purchase of Trillium Therapeutics and this was marked by a commitment to empower its oncology pipeline using innovative immuno-oncology assets. For Pfizer, this deal forms part of its wider corporate strategy that seeks to enhance its range of cancer drugs for rare neoplasms such as chordoma (Stock Market News Live | Stock Titan)​.

Novartis declared positive results from ASCLEPIOS trial Phase III for asciminib as an inhibitor of STAMP kinase in chronic myeloid leukemia (CML). This leap affirms Novartis’s bespoke approach to targeted treatments that may have implications on the way it handles other types of cancer including chordoma​ (Stock Market News Live | Stock Titan)​.

November 2022 saw Blueprint Medicines announce favorable findings from phase I/II study with BLU-667 (pralsetinib) on individuals suffering from cancers positive for RET fusions. These achievements underline the company’s focus on precision oncology that could go towards handling rarer forms like chordoma​.

July 2023: Horizon Therapeutics plc has revealed the 50 recipients of the 2023 #RAREis™ Global Advocate Grant, who were chosen from various countries worldwide. The rare disease patient advocacy organizations will be awarded a single grant of $5,000 to initiate new programs, provide educational resources, and enhance their existing services in order to provide greater assistance to their respective disease communities. Applications are assessed according to the organization's efforts in assisting the rare disease community and how the funding would enhance their capacity to achieve their objectives and aims. The #RAREis Global Advocate Grant is a component of Horizon's #RAREis initiative, which aims to enhance the quality of life for those with rare diseases. This grant provides assistance to various organizations that deliver essential programs and services for individuals affected by rare diseases. The Global Advocate Grant program was initiated in 2022 with the aim of provide essential financial support and promoting fairness for the rare disease community. Its primary objective is to facilitate the development of advocacy organizations worldwide. Horizon is an international biotechnology corporation that specializes in finding, creating, and selling medications that specifically target the urgent requirements of individuals affected by uncommon, autoimmune, and severe inflammatory illnesses.

Chordoma Disease Market Trends

• Growing elderly population is driving the market growth

Market CAGR for chordoma disease is being driven by the rising elderly population. The rise in the elderly population, rising government initiatives, investments in R&D by pharmaceutical companies, and demand for minimally invasive surgery for chordoma treatment are projected to be the main factors driving market expansion. The absence of health insurance coverage, cost increases, and side effects from radiation and chemotherapy therapy are anticipated to impede market expansion. Opportunities anticipated to support the market growth include the emergence of unexplored markets, the growth of emerging markets in developing nations, the opening of new healthcare facilities, and the development of novel therapeutics.

Men are shown to have a higher prevalence than women by a factor of two. Additionally, most tumor instances happen in people between 50 and 70. About two out of every five chordomas (40%) spread in the area of the skull, while the remaining chordomas grow in the spine's vertebrae. The Endoscopic Endonasal Approach (EEA), created by UPMC, is the surgical procedure of choice for chordomas of the base of the skull. The inoperable tumors are reached using this minimally invasive approach by passing through the nasal canals. The advantages of EEA surgery include quicker healing, no deformity, and no incisions to close.Over the projection period, the market would experience growth due to the increasing number of bone cancer incidences. For instance, primary bone cancer is uncommon and makes up considerably less than 1% of all newly diagnosed tumors, according to the National Cancer Institute. According to the American Cancer Society's forecast for 2022, there will be 3,910 new cases of bone cancer diagnosed in the USA, leading to 2,100 fatalities. Less than 1% of all malignancies are primary bone cancers, rare cancers that begin in the bones. Adults are more likely to develop secondary bone cancers (often called bone metastases) than primary ones.

Government programs for treating bone cancer are anticipated to grow in the market. For instance, the VERDI project, supported by the European Commission, created inventive multifunctional nanoplatforms that may mend difficult-to-treat bone ailments utilizing a special, adaptable, and scalable technology. The Innovative Manufacturing Cooperative Research Centre (IMCRC) donated $A2.36 million in cash, and Stryker jointly sponsored the project. Therefore, the industry is being driven by an increase in government activities.Thus, driving the Chordoma Disease market revenue.

Chordoma Disease Market Segment Insights

Chordoma Disease Diagnosis Insights

Based on the diagnosis, the  Chordoma Disease market segmentation includes biopsy, imaging, and blood tests. The biopsy segment dominated the market, accounting for 35% of market revenue. This screening method has greatly improved the diagnosis of skin, breast, and prostate cancer. The demand for and supply of biopsy devices have increased due to increased cancer occurrences worldwide. A  movement in consumer preferences towards minimally invasive surgical techniques, brought on by an increasing understanding of their advantages—including shorter recovery times, smaller incisions, and less pain and scarring—also drives investment in the field. 

Chordoma Disease Treatment Insights

The  Chordoma Disease market segmentation, based on treatment, includes chemotherapy, radiation therapy, cryosurgery, surgery, and targeted therapy. The chemotherapy segment dominated the market. Rising consumable usage, rising R&D costs, an increase in older adults, and the introduction of technologically sophisticated diagnostic kits and reagents. 

Chordoma Disease End User Insights

Based on end users, the  Chordoma Disease market segmentation includes hospitals, clinics, and cancer care centers. The hospitals generated the most income. Factors like rising personalized medicine awareness increased accessible healthcare services, and strategic initiatives. With one of the largest geographic reach and the ability to treat over 115,000 patients annually, the combined organization will rank among the top treatment and research centers in the United States.

Figure 1  Chordoma Disease Market, by End User, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Chordoma Disease Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Chordoma Disease market will dominate this market; because there are now several clinical trials for bone cancer treatments taking place in the region, mostly in the United States, it is anticipated that the region will expand its market share. New chemotherapies are being tested in several studies. Researchers are also considering novel applications for the portfolio of currently approved medicines.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  CHORDOMA DISEASE MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Chordoma Disease market accounts for the second-largest market share due to ongoing technological developments in cancer diagnoses. Further, the German Chordoma Disease market held the largest market share, and In all of Europe, the market for Chordoma Disease in the UK has the quickest expansion rate.

Between 2023 and 2032, the market for Chordoma Disease in Asia-Pacific is anticipated to develop quickly. This is because of the strategic actions taken by major companies, the significant growth in cervical screening programs run to raise awareness and screening, the increase in R&D, and technical developments. Moreover, China’s Chordoma Disease market held the largest market share, and the Indian Chordoma Disease market was the fastest-growing market in the Asia-Pacific region.

Chordoma Disease Key Market Players & Competitive Insights

Leading industry companies are making significant R&D investments to diversify their product offerings, which will drive the Chordoma Disease market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Chordoma Disease industry must provide affordable products to grow and thrive in a more competitive and challenging market environment.

Local manufacturing to cut operating costs is one of the key business tactics manufacturers use in the  Chordoma Disease industry to help clients and expand the market sector. Major players in the Chordoma Disease market, including Bavarian Nordic and others, are attempting to increase market demand by investing in research and development operations.

Bavarian Nordic is a fully integrated biotechnology firm dedicated to creating novel, risk-free treatments for cancer and infectious disorders. They have developed a wide range of proprietary and co-developed product candidates to enhance the health and quality of life of children and adults using their live viral vaccine platform, MVA-BN. They provide the Strategic National Stockpile of the United States and other government stockpiles with its non-replicating smallpox vaccine, IMVAMUNE. The vaccine is authorized in Canada and the European Union (where it is sold under IMVANEX). The United States is now conducting registration studies. The United States is now conducting registration studies. Their infectious disease pipeline includes a proprietary RSV program in addition to vaccine candidates for Ebola, HPV, HBV, and HIV, which are developed through a strategic partnership with Janssen, in addition to their long-standing collaboration with the U.S. government on the development of IMVAMUNE and other medical countermeasures. Additionally, in partnership with the National Cancer Institute, they have created a portfolio of active cancer immunotherapies that aim to change the course of the disease by inducing a strong and widespread anti-cancer immune response while preserving an advantageous risk-benefit profile. The U.S. (FDA) granted orphan drug status to Bavarian Nordic A/S's BN-Brachyury, a brand-new cancer vaccine recommended for the treatment of chordoma.

The primary goals of Guangzhou, China's top biotechnology company, Bio-Thera Solutions Ltd., are the research and development of novel therapeutics for the treatment of cancer, cardiovascular,autoimmune,  and various other serious unmet medical needs, and the development of biosimilars for currently available, labeled biologics to treat many kinds of cancer-related and autoimmune disorders. The business, a pioneer in developing next-generation antibodies, has moved five candidates into late-stage clinical trials and submitted an application for marketing authorization for one candidate. The company also has several interesting candidates in early clinical trials and IND-enabling investigations, concentrating on novel targets in autoimmune and immuno-oncology illnesses. In January 2019 According to a licensing agreement between Bio-Thera Solutions Ltd. (hereafter referred to as "Bio-Thera") and Cipla Limited for BAT1706, a bevacizumab biosimilar, Cipla will have the sole right to market and distribute the medication in a few emerging regions. Currently licensed for six indications, including metastatic colorectal cancer, recurrent glioblastoma, and non-squamous non-small cell lung cancer, BAT-1706 is a mAb biosimilar of Genentech's Avastin.

Key Companies in the Chordoma Disease market include

• AstraZeneca plc (U.K.)


• Amgen, Inc. (U.S.)


• Actavis plc (U.S.)


• Bristol-Myers Squibb and Company (U.S.)


• Celgene Corporation (U.S.)


• Eli Lilly and Company (U.S.)


• Hoffmann-La Roche AG (Switzerland)


• GlaxoSmithKline plc (UK)


• Novartis International AG (Switzerland)


• Pfizer, Inc. (U.S.)


• Sanofi S.A. (France)


• Debiopharm Group (Switzerland)


• Bayer AG (Germany)


• Johnson & Johnson (U.S.)


• Merck & Co., Inc. (U.S.)


• Optivus Proton Therapy, Inc. (U.S.)


• ProCure Treatment Centers, Inc. (U.S.)


• Varian Medical Systems, Inc.(U.S.)


• Amura Holdings Ltd. (U.S.)


• Catena pharmaceuticals Inc. (U.S.)


• Celldex therapeutics Inc. (U.S.)


• Eckert & Ziegler BEBIG (Germany)


• Infinity Pharmaceuticals (U.S.)


• Medivir AB (Sweden)


• Merrion Pharmaceuticals Plc. (U.S.).

Chordoma Disease Market Segmentation

Chordoma Disease Diagnosis Outlook

• Biopsy


• Imaging


• Blood Tests

Chordoma Disease Treatment Outlook

• Chemotherapy


• Radiation Therapy


• Cryosurgery


• Surgery


• Targeted Therapy

Chordoma Disease End User Outlook

• Hospital


• Clinic


• Cancer Care Centers

Chordoma Disease Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America